These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12655326)

  • 1. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.
    Gründer G; Vernaleken I; Müller MJ; Davids E; Heydari N; Buchholz HG; Bartenstein P; Munk OL; Stoeter P; Wong DF; Gjedde A; Cumming P
    Neuropsychopharmacology; 2003 Apr; 28(4):787-94. PubMed ID: 12655326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
    Holcomb HH; Cascella NG; Thaker GK; Medoff DR; Dannals RF; Tamminga CA
    Am J Psychiatry; 1996 Jan; 153(1):41-9. PubMed ID: 8540590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
    Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
    Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.
    Vernaleken I; Kumakura Y; Cumming P; Buchholz HG; Siessmeier T; Stoeter P; Müller MJ; Bartenstein P; Gründer G
    Neuroimage; 2006 May; 30(4):1332-9. PubMed ID: 16439159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects.
    Vernaleken I; Kumakura Y; Buchholz HG; Siessmeier T; Hilgers RD; Bartenstein P; Cumming P; Gründer G
    Neuroimage; 2008 Apr; 40(3):1222-31. PubMed ID: 18262797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
    Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
    Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET.
    Nozaki S; Kato M; Takano H; Ito H; Takahashi H; Arakawa R; Okumura M; Fujimura Y; Matsumoto R; Ota M; Takano A; Otsuka A; Yasuno F; Okubo Y; Kashima H; Suhara T
    Schizophr Res; 2009 Mar; 108(1-3):78-84. PubMed ID: 19056247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
    Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
    Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography.
    Elkashef AM; Doudet D; Bryant T; Cohen RM; Li SH; Wyatt RJ
    Psychiatry Res; 2000 Nov; 100(1):1-11. PubMed ID: 11090720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.
    Karlsson P; Farde L; Halldin C; Sedvall G
    Am J Psychiatry; 2002 May; 159(5):761-7. PubMed ID: 11986129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S; Hirschowitz J; Machac J
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
    Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]DOPA formed from [3H]tyrosine in living rat brain is not committed to dopamine synthesis.
    Cumming P; Ase A; Kuwabara H; Gjedde A
    J Cereb Blood Flow Metab; 1998 May; 18(5):491-9. PubMed ID: 9591841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.